Underutilization of HeartMate 3 LVAD in Advanced Heart Failure
In this episode of Between Two Ventricles™ HF Podcast, Michael Zhen-Yu Tong, M.D., MBA, FRCSC, and Dr. Phil Adamson emphasize how median survival with HeartMate 3 LVAD reliably exceeds 5 years, even in those patients with refractory heart failure who are ineligible for transplantation.
Listen to the Podcast